- Drugs
- Wednesday, 26 Feb 2020
Purina Pro Plan Announces the First and Only Allergen-Reducing Cat Food
Purina Pro Plan will introduce a revolutionary approach in the management of cat allergens in April: Purina Pro Plan LiveClear, the first and only cat food that reduces the allergens in cat hair and dander. This breakthrough diet is the culmination of more than a decade of Purina research dedicated to finding a safe, effective way to address a problem that impacts countless cat-owning households worldwide. When fed daily, LiveClear significantly reduces the allergens in cat hair and dander in as little as three weeks. It is outstanding nutrition that has the power to change lives, helping cat owners be closer together with the cats they love.
Managing cat allergens is a struggle for the one in five adults worldwide who are sensitized to cat allergens.1,2 This can limit the interactions between owners and their cats, as current methods for managing cat allergens often include limiting the time or activities with the cat, isolating the cat in the home or removing the cat from the home altogether.
"Many people think that cat hair is the root of their problem," explained Ebenezer Satyaraj, PhD, immunologist for Nestlé Purina Research and lead investigator on the research that led to the development of Pro Plan LiveClear, "but it's actually what's on it – the major cat allergen called Fel d 1, a protein that cats produce naturally in their saliva." 3,4
All cats produce Fel d 1, regardless of breed, age, hair length, sex or body weight.4-6 When cats groom, Fel d 1 gets on the hair and skin through the saliva, and eventually into the environment.
The key ingredient in Pro Plan LiveClear is a specific protein sourced from eggs. When cats eat LiveClear, the protein binds to the Fel d 1 and safely neutralizes it in the cat's mouth. By reducing active Fel d 1 in the cat's saliva, it reduces the allergen that is transferred to the cat's hair and dander when they groom, ultimately reducing the allergen in the environment. 7,8
In a published study, feeding Pro Plan LiveClear was shown to reduce the allergens in cat hair and dander by an average of 47%, starting in the third week of daily feeding.7
Cat safety was critically important when developing the product. "As a cat lover and veterinarian, my focus is on the health and safety of the cats under my care. The beauty of Pro Plan LiveClear is that it reduces cat allergens in cat hair and dander without impacting the physiology of the cat," explained Kurt Venator, Chief Veterinary Officer at Purina. "Because scientists don't know exactly why cats produce Fel d 1, our goal was to neutralize it rather than inhibit its production." A 6-month safety study also showed that the egg product ingredient coating the LiveClear kibble is completely safe for cats to eat.9 The action happens in the cat's mouth, but once swallowed, the ingredient is digested like any other protein.
Pro Plan LiveClear is not intended to replace other allergen-reduction strategies but, rather, to add another measure that can help reduce the allergen burden in cat households. With this groundbreaking approach to cat allergen management, the quality of life for cats and the families that love them can enable closer contact than ever before.
Purina Pro Plan LiveClear is a 100% complete and balanced dry cat food with outstanding taste and nutrition designed for daily feeding. It will be available at Chewy, PetSmart, Petco, Pet Supplies Plus and other pet specialty retailers in three formulas – Adult Chicken & Rice, Adult Salmon & Rice, and Adult Sensitive Skin & Stomach Turkey & Oat Meal. At launch, Pro Plan LiveClear can be purchased in the United States, with availability in other markets later in 2020.
Related Industry Updates
Doctors and health experts urged people not to drink or inject disinfectant
Apr 24, 2020
Athlete Endorsements Help Drive the CBD Industry to New Heights
Oct 25, 2019
Patient-Derived Xenograft Model Market is expected to reach US$ 975.31 million by 2030
Feb 06, 2024
Epilepsy Market is expected to reach US$ 10.7 billion by 2030
Feb 14, 2024
Sanofi says COVID-19 vaccine will be available globally at the same time
May 15, 2020
North America Vaccines Market is Estimated to Grow with a CAGR of 6.0% from 2019-2027
Sep 25, 2020
Microbiome Therapeutics Market is expected to reach US$ 813.38 million by 2030
Nov 08, 2023